PACMAN-AMI trial: review of endpoints
Authors:
Roman Margóczy 1,2
Authors‘ workplace:
II. klinika kardiológie a angiológie, LF Slovenskej zdravotnickej univerzity, Bratislava
1; Oddelenie funkčnej diagnostiky, Stredoslovenský ústav srdcových a cievnych chorôb, Banská Bystrica
2
Published in:
AtheroRev 2022; 7(3): 156-158
Category:
Clinical Studies
Overview
Timely addition of alirocumab to high-intensity statin therapy in patients with myocardial infarction resulted in lipid profile improvement and significantly greater percent atheroma volume regression, assessed by combination of three intracoronary imaging modalities.
Keywords:
alirocumab – fibrous cap thickness (FCT) – intravascular ultrasonography (IVUS) – maximal lipid core burden index (maxLCBI) – near infrared spectroscopy (NIRS) – optical coherence tomography (OCT) – percent atheroma volume (PAV)
Sources
1. Räber L, Ueki Y, Otsuka T et al. Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial. JAMA 2022; 327(18): 1771–1781. Dostupné z DOI: <http://10.1001/jama.2022.5218>.
Labels
Angiology Diabetology Internal medicine Cardiology General practitioner for adultsArticle was published in
Athero Review
2022 Issue 3
Most read in this issue
- Bempedoic acid – a new drug to lower LDL-cholesterol level
- Newer possibilities of slowing the development of chronic kidney disease and the role of dapagliflozin
- Statement CSAT on Consensus EAS 2021: Triglyceride-rich lipoproteins and their remnants – metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies
- XXXVI. konference o hyperlipoproteinemiích – Šobrův den 2022